EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--May 10, 2006--SurModics, Inc. (Nasdaq:SRDX - News), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it has granted Bausch & Lomb (NYSE:BOL - News) an exclusive license to patents relating to the use of Genistein in the treatment and prevention of retinal diseases. Technology relating to the use of Genistein was among the technologies acquired by SurModics in connection with the acquisition of InnoRx in January 2005. InnoRx had licensed patents covering inventions made by InnoRx founder and renowned retinal surgeon Eugene de Juan, Jr., M.D. Terms of the agreement are confidential.
